# US 2016/0250343 A1 · Combination therapy for treatment of cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250343 A1
- Document ID: US20160250343A1
- Status: Published application
- Kind: A1
- Application number: 15/055,940
- Filed: 2016-02-29
- Published: 2016-09-01
- Earliest claimed: 2011-05-17
- Assignees: University of South Alabama
- Applicants: University of South Alabama
- Inventors: Hung T. Khong
- Web page: https://patentgrep.com/patent/US20160250343A1

## CPC

- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent.

## Claims

### Claim 1

A method of treating a cancer in a subject in need thereof comprising:
administering a chemotherapeutic agent associated with or bound to albumin;
administering a second chemotherapeutic agent; and
administering a third chemotherapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered periodically.

### Claim 3 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin the second chemotherapeutic agent and a third chemotherapeutic agent are administered on the same day and subsequently the chemotherapeutic agent associated with or bound to albumin is administered periodically without the second chemotherapeutic agent and the third chemotherapeutic agent.

### Claim 4 (depends on 1)

The method of claim 1, wherein on some occasions the chemotherapeutic agent associated with or bound to albumin the second chemotherapeutic agent and a third chemotherapeutic agent are administered on the same day and on other occasions only the chemotherapeutic agent associated with or bound to albumin is administered.

### Claim 5 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin comprises an agent selected from the group consisting of paclitaxel, docetaxel, and rapamycin.

### Claim 6 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is Abraxane.

### Claim 7 (depends on 1)

The method of claim 1, wherein the second chemotherapeutic agent comprises a topoisomerase inhibitor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the topoisomerase inhibitor is doxorubicin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the third chemotherapeutic agent comprises an alkylating agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the alkylating agent is cyclophosphamide.

### Claim 11 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered on days 1 and 8.

### Claim 12 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered on days 1, 8, 15.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered on days 1, 8, and 22.

### Claim 16 (depends on 1)

The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered at an interval of at least about 5 days.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 2)

The method of claim 2, wherein the periodic administration comprises at least 2 cycles.

### Claim 20

(canceled)

### Claim 21 (depends on 3)

The method of claim 3, wherein the chemotherapeutic agent associated with or bound to albumin the second chemotherapeutic agent and the third chemotherapeutic agent are administered on the same day and subsequently the administration of the chemotherapeutic agent associated with or bound to albumin is repeated for a plurality of cycles.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 21)

The method of claim 21, wherein each cycle for the subsequent administration of the chemotherapeutic agent associated with or bound to albumin comprises at least about 5 days.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28 (depends on 1)

The method of claim 1, wherein at least about 100 mg/m2 Abraxane is administered on day 1 and 8, at least about 50 mg/m2 doxorubicin is administered on day 1, and at least about 500 mg/m2 cyclophosphamide is administered on day 1.

### Claim 29 (depends on 28)

The method of claim 28, further comprising administering Pegfilgrastim on day 9.

### Claim 30 (depends on 1)

The method of claim 1, wherein said cancer is breast cancer.

### Claim 31 (depends on 1)

The method of claim 1, wherein the cancer is HER2 negative breast cancer.

### Claim 32 (depends on 1)

The method of claim 1, wherein the cancer is triple negative breast cancer.

### Claim 33 (depends on 6)

The method of claim 6, wherein the dose of Abraxane is between about 50 mg/m2 and about 200 mg/m2.

### Claim 34 (depends on 6)

The method of claim 6, wherein the dose of Abraxane is selected from the group consisting of 100 mg/m2 and 150 mg/m2.
